 REDWOOD CITY, Calif.--BUSINESS WIRE--Guardant Health, Inc. Nasdaq: GH adds two new products to its portfolio to help improve the management of patients with late-stage and metastatic cancers. The Guardant360 ResponseTM test represents a breakthrough as the first commercially available, blood-only, liquid biopsy test that detects changes in circulating tumor DNA ctDNA levels to provide oncologists an early indication of a patients response to treatment. The Guardant360 TissueNextTM test, th 